Novo (NVO) Announces Investment in Ireland To Boost Production

0
106

​Novo Nordisk A/S (NYSE:NVO) is one of the Best Value Stocks to Buy for the Long Term. On March 2, Novo Nordisk A/S (NYSE:NVO) announced a €432 million (DKK 3.2 billion) investment in its Monksland facility in Athlone, Ireland, to boost production of oral GLP-1 treatments.

​Management noted that this investment will allow the company to have a hub to serve international markets outside of the US. The investment is aimed at retrofitting the existing tableting plant, adding capacity for current and future GLP-1 drugs like oral Semaglutide. The company has already started construction on the 45-acre site and is expected to wrap up gradually from late 2027 to 2028.

​Management also highlighted that the already recruited 260 employees at the site are expected to prioritize high-quality, sustainable oral treatments, while the construction is projected to create up to 500…

Read more…

LEAVE A REPLY

Please enter your comment!
Please enter your name here